Back to top
more

Editas Medicine (EDIT)

(Delayed Data from NSDQ)

$3.19 USD

3.19
2,265,425

+0.23 (7.77%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $3.19 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

3 Biotech Technological Developments to Watch Out For in 2021

by Kinjel Shah

Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021

Kinjel Shah headshot

5 Disruptive Biotech Stocks With Solid Long-Term Potential

by Kinjel Shah

Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.

Sweta Killa headshot

Top ETF of December & Its Best Stocks

by Sweta Killa

We have highlighted the best ETF of December and its best performing stocks.

Ekta Bagri headshot

5 Biotech Stocks That More Than Doubled This Year

by Ekta Bagri

The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.

Kevin Cook headshot

CRISPR Gene Editing: Owning the Future of Medicine

by Kevin Cook

In the Century of Biology, it pays to own the future of curing disease at the root.

Editas (EDIT) Submits Application to Start Study on EDIT-301

by Zacks Equity Research

Editas (EDIT) files an IND application to the FDA for beginning a phase I/II study of EDIT-301 to treat SCD.

CRISPR (CRSP) Up on Promising Data for Gene Therapy CTX001

by Zacks Equity Research

CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows sustained response to treatment in patients with transfusion-dependent beta thalassemia as well as sickle cell disease. Shares rise.

Editas (EDIT) Up 9.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in Focus

by Zacks Equity Research

Editas' (EDIT) bottom line grows year over year in the third quarter while revenues beat estimates. Stock rises is after-hours trading.

Editas Medicine (EDIT) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 118.18% and 759.42%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher

Booming Gene Editing Market to Pep Up These 5 Biotech Stocks

by Zacks Equity Research

Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.

Amgen Down on Unsatisfactory Heart Failure Drug Study Results

by Zacks Equity Research

Amgen (AMGN) with partners post top-line data from the phase III GALACTIC-HF study on omecamtiv mecarbil, which is being evaluated for heart failure with reduced ejection fraction. Stock falls.

BioMarin (BMRN) Gets FDA Approval for Higher Dose of Palynziq

by Zacks Equity Research

The FDA approves higher dose (60 mg) of BioMarin's (BMRN) Phenylketonuria drug Palynziq injection. The regulatory nod includes the addition of longer-term efficacy data on Palynziq's label.

Kevin Cook headshot

Big October Winners: CRISPR, Alteryx, NVIDIA, Quidel

by Kevin Cook

Two women will share the Nobel prize for a gene editing technology that will change the world.

CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status

by Zacks Equity Research

CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals' CRISPR/Cas9 gene-editing therapy candidate, CTX001, gets Priority Medicines designation for treating sickle cell disease.

Kevin Cook headshot

CRISPR Stocks: Buy or Trade?

by Kevin Cook

Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?

Why Is Editas (EDIT) Down 17.3% Since Last Earnings Report?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas' SCD Candidate Gets FDA's Rare Pediatric Disease Tag

by Zacks Equity Research

The FDA bestows a Rare Pediatric Disease designation on Editas' (EDIT) experimental candidate EDIT-301, which is being developed for treating sickle cell disease.

Editas' (EDIT) Earnings Beat in Q2, Revenues Improve Y/Y

by Zacks Equity Research

Editas' (EDIT) both bottom and the top line better estimates for the second quarter of 2020.

Earnings Preview: Editas Medicine (EDIT) Q2 Earnings Expected to Decline

by Zacks Equity Research

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Editas (EDIT) in Focus: Stock Moves 8.6% Higher

by Zacks Equity Research

Editas (EDIT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Editas (EDIT) Up 10.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas (EDIT) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Editas (EDIT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Editas' (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y

by Zacks Equity Research

Editas (EDIT) beats on earnings in the first quarter of 2020 while revenues slightly miss estimates.